Melanoma

This early-stage trial tests a personalized cancer vaccine for people with bladder or stomach cancer who still have tiny amounts of cancer DNA in their blood after surgery. The vaccine is made from unique proteins in each person's tumor and aims to train the immune system to find…

This early-phase trial tests a new mRNA vaccine called PAN-NeoVax, designed by artificial intelligence to target multiple cancer types. The vaccine is injected directly into tumors in 9 patients with advanced solid cancers who have run out of standard options. The main goal is to…

Researchers are testing whether a blood test for circulating tumor DNA (ctDNA) can help decide when patients with advanced melanoma can safely stop immune checkpoint inhibitor therapy. The study enrolls adults whose tumors have responded to or stabilized on these drugs for at lea…

This phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…

This early-stage trial tests whether injecting gold nanoparticles into tumors, followed by radiation and an immunotherapy drug, is safe for people with advanced melanoma. Only 6 participants will be enrolled. The goal is to check for side effects, not to see if the treatment work…

This early-stage trial tests whether a stool transplant (FMT) can help cancer patients who develop severe diarrhea or colon inflammation from immune-checkpoint inhibitor drugs. About 40 patients with various cancers will receive the transplant via colonoscopy. The main goal is to…

This early-phase trial is testing an experimental drug called BI-1808, alone or with the immunotherapy pembrolizumab (Keytruda), in people with advanced cancers like ovarian cancer, T-cell lymphoma, and melanoma. The main goals are to check safety, find the best dose, and see how…

This early-stage trial is testing whether an oral probiotic called R-5780 is safe and tolerable when taken alongside a standard PD-1 checkpoint inhibitor in people with advanced solid tumors (like melanoma or certain skin cancers). About 33 adults whose cancer has not responded t…

This study tests a new drug called AU-007 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is designed to help the immune system fight cancer. About 159 participants will receive AU-007 alone or with other medicines to find the safes…

This phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…

This Phase 2 trial tests whether combining pembrolizumab (an immunotherapy) with aldesleukin (IL-2) can shrink tumors in people with advanced melanoma or kidney cancer that hasn't responded to prior treatments. About 78 adults will receive two cycles of the combo in the hospital,…

This phase 2 trial tests a drug called BMS-986504 in people with advanced solid tumors that have lost a gene called MTAP. The drug is given alone or with other cancer medicines. The study aims to see if the drug shrinks tumors and how safe it is. About 260 adults will take part.

This early-phase trial tests whether giving different drug combinations after surgery, based on how well the tumor responded to initial treatment, can reduce the risk of melanoma returning. About 50 adults with stage III or IV BRAF-mutant melanoma will receive encorafenib, binime…

This study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…

This study tests an oral drug called NEO212 in people with specific brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control tumor growth. About 134 adults will take NEO212 alone or with sta…

This phase 2 trial is testing a drug called tebentafusp in 19 people with a rare eye cancer (uveal melanoma) that has spread to the liver. Participants receive weekly infusions for 6 months, then may have surgery to remove any remaining tumors. The goal is to see if the drug can …

This study provides continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to track long-term side effects and safety over ti…

This early-stage trial tests a personalized cell therapy called lifileucel for people with advanced uveal melanoma (a rare eye cancer) or certain sarcomas (connective tissue cancers). The treatment involves removing immune cells from the patient's tumor, growing them in a lab, an…

This study tests whether adding a fecal microbiota transplant called LND101 to standard immunotherapy can help stop advanced melanoma from growing or spreading. About 128 people with stage IV or unresectable melanoma will receive either immunotherapy alone or immunotherapy plus L…

This early-phase trial tests SL-28, a cell therapy made from donor immune cells, in 60 people with advanced solid tumors (like lung, pancreatic, or breast cancer) that haven't responded to standard treatments. The study aims to find a safe dose and see if the therapy can shrink t…

This phase 2 trial compares two treatment combinations for people with BRAF-V600 mutant melanoma that has spread to the brain. One group gets a targeted therapy (encorafenib and binimetinib) plus an immunotherapy (nivolumab), while the other gets two immunotherapies (ipilimumab a…

This early-phase trial tests a new drug called BI 3810944 in adults with advanced solid tumours or melanoma who have no other treatment options. The study aims to find a safe and tolerable dose, and to see if the drug can shrink tumours. Participants receive the drug every three …

This study is testing a new experimental drug called GI-101, given alone or with pembrolizumab or lenvatinib, in people with advanced or metastatic solid tumors (cancers that have spread). The goal is to see if the drug is safe and can shrink or control tumors. About 317 adults w…

Researchers are testing whether combining SX-682, an experimental drug that blocks CXCR1 and CXCR2, with proton craniospinal irradiation is safe and effective for people with leptomeningeal disease from melanoma or non-small cell lung cancer. Participants take SX-682 by mouth twi…

This study looks at how a highly targeted form of radiation called stereotactic radiosurgery (CyberKnife) works alongside newer treatments like immunotherapy and targeted therapy for people with melanoma that has spread to the brain. Researchers will observe 50 patients over time…

This study tests whether adding AGuIX gadolinium-based nanoparticles to standard brain radiation can better control brain metastases that are at high risk of coming back. About 134 adults with certain cancers (like melanoma, lung, breast, or colorectal) that have spread to the br…

This study tests a new treatment called DOC1021 for people with advanced melanoma that has not responded to standard therapy. DOC1021 is a personalized vaccine made from a patient's own blood and tumor cells, designed to teach the immune system to attack the cancer. The trial wil…

This trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …

This early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…

This study tests two oral drugs, AMXT 1501 and DFMO, given alongside standard treatments for people with advanced solid tumors (breast cancer or melanoma) that have worsened after prior therapies. The goal is to find a safe dose and see if the combination helps shrink tumors or s…

This early-phase trial is testing a new drug called KIN-2787 (exarafenib), alone or combined with another drug (binimetinib), in 400 adults with advanced solid tumors that have BRAF or NRAS mutations. The main goals are to check safety, find the best dose, and see if the drug can…

This study tests a new drug called BNT326, given alone or with other cancer immunotherapies, in about 980 adults with advanced solid tumors that have spread or come back after prior treatment. The goal is to find the best dose and see if it is safe and effective. It is an early-s…

This phase 2 trial tests whether injecting two experimental immune drugs, L19IL2 and L19TNF, directly into tumors can help people with advanced melanoma that no longer responds to standard immunotherapy. Participants receive one of the injected drugs or a combination of both, alo…

This study tests whether combining a liver-directed chemotherapy (HEPZATO KIT) with an immunotherapy drug (Opdualag) is safe and effective for people with metastatic melanoma that has spread to the liver. About 15 participants who have not received prior systemic treatment will r…

This study tests a new way to deliver radiation therapy for people with lung cancer, melanoma, or kidney cancer that has started to grow again in a few spots despite treatment. The approach uses a PET scan to find the most active parts of the tumor and delivers a higher radiation…

This study tests a combination of two immunotherapy drugs (nivolumab and ipilimumab) along with two anti-rejection medications (sirolimus and prednisone) in kidney transplant recipients who have advanced skin cancer that cannot be surgically removed or has spread. The goal is to …

This phase 2 trial tests a new treatment called LM103 TILs, made from a patient's own immune cells, for advanced melanoma that hasn't responded to standard therapies. About 92 adults will be randomly assigned to receive either the TIL therapy or standard care. The study aims to s…

This trial tests whether combining three immunotherapy drugs, nivolumab, relatlimab, and ipilimumab, can safely and effectively treat metastatic melanoma as a first-line therapy. Researchers will enroll about 30 adults with advanced melanoma to find the best dose of the triplet a…

This study tests whether freezing part of a growing tumor (cryoablation) can help two immunotherapy drugs, ipilimumab and nivolumab, work better in people with advanced melanoma that has stopped responding to initial treatment. About 37 adults whose melanoma is growing despite pr…

This study tests whether one dose of the immunotherapy drug pembrolizumab, given before standard surgery, can shrink or eliminate tumors in people with stage IIb/c melanoma. About 30 adults with thick melanomas that haven't spread to lymph nodes will receive either pembrolizumab …

This study tests a drug called tegavivint in children, teens, and young adults whose solid tumors have come back or stopped responding to treatment. The goal is to find the safest dose and see if it can shrink tumors by blocking a key growth signal inside cancer cells. About 147 …

This study is testing the drug T-DXd (Enhertu) in 100 adults with advanced HER2-positive solid tumors who have already tried other treatments and have no good options left. The goal is to see how well the drug works in real-world settings, including how many patients respond and …

This early-phase study is testing two drugs together — alpelisib and pembrolizumab — in people with metastatic breast cancer or melanoma that has spread to the brain or other organs. The main goal is to find a safe dose and see what side effects occur. Up to 50 adults whose cance…

This study tests whether a simple blood test that looks for tumor DNA (ctDNA) can help doctors decide when to add a third immunotherapy drug (ipilimumab) to a two-drug combination (nivolumab and relatlimab) for people with advanced melanoma. About 90 adults with metastatic or adv…

This trial tests AVT32-DRL_PB, a biosimilar (copy) of the cancer drug Keytruda, in 120 people with stage IIB/C or III melanoma whose tumors were fully removed. Half get the biosimilar, half get Keytruda, every 3 weeks. The main goal is to see if drug levels in the blood are simil…

This Phase 1 trial tests two experimental mRNA immunotherapies, mRNA-4106 and mRNA-4200, in about 42 people with advanced solid tumors. Unlike personalized cancer vaccines made from a patient's own tumor mutations, these are off-the-shelf therapies designed to target shared antig…

This study tests a personalized vaccine made from a patient's own tumor proteins, given alone or with the immunotherapy drug pembrolizumab. The goal is to see if the combination is safe and helps the immune system attack advanced solid tumors. About 132 people with various advanc…

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 53 adults aged 18 to 72 who have already tried at least one other treatment will take part. …

This phase 2 trial tests whether adding an experimental immune-boosting pill (PRTX007) to standard immunotherapy (pembrolizumab) before surgery can improve outcomes for people with stage III melanoma. About 48 adults with resectable melanoma will take the combination for 9 weeks …

This early-phase study tests two drugs—ulixertinib and palbociclib—together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find a safe dose and check for side effects. About 45 adults whose cancers have not responded t…

This study tests whether a new combination of drugs (fianlimab and cemiplimab) works better than an already approved treatment (Opdualag) for people with advanced melanoma that cannot be removed by surgery or has spread. About 560 adults with previously untreated melanoma will re…

This study looks at whether high-intensity exercise and a high-fiber diet are practical and helpful for people with advanced melanoma who are receiving immunotherapy. About 40 adults will be assigned to exercise, diet changes, both, or standard care. The goal is to see if these l…

This study tests a new drug, AZD6750, that helps the immune system fight cancer. It is for adults with advanced solid tumors like melanoma, lung, or breast cancer that have not responded to other treatments. The goal is to find the safest dose and see if it shrinks tumors when us…

This study tests an experimental drug called JMT108 in people with advanced melanoma that cannot be removed by surgery or has spread. The goal is to check if the drug is safe and helps shrink tumors. About 188 adults who have tried other treatments without success will receive JM…

This phase II trial is testing whether combining two drugs, binimetinib and imatinib, can shrink tumors in people with advanced KIT-mutant melanoma that cannot be removed by surgery. The study will enroll 25 participants with stage III or IV melanoma. The goal is to see how many …

This study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…

This early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…

This trial investigates whether giving standard combination immunotherapy (ipilimumab and nivolumab) in the early morning (before 10 AM) versus the afternoon (after 1 PM) improves tumor response in people with advanced melanoma. About 170 participants with metastatic or inoperabl…

This study tests a new treatment for adults with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, modify your white blood cells in a lab to recognize and attack CD70, and then give them back t…

This early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…

This trial tests whether a six-month program of supervised resistance exercise and personalized nutritional support can help adults with stage II to IV melanoma preserve muscle mass and quality while starting immunotherapy. Participants are randomly assigned to either the exercis…

This early-stage study tests a new drug called KUP-101A in 21 people with advanced skin cancers (like melanoma or Merkel cell carcinoma) that have not responded to other treatments. The main goals are to find the safest dose and check for side effects. Researchers will also measu…

This trial tests an experimental drug called STAR0602, which is designed to help the immune system attack cancer cells. It is being studied in people with advanced solid tumors that have not responded to standard treatments. The drug is given alone or combined with chemotherapy, …

This early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…

This early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…

This phase 2 trial is testing whether adding hydroxychloroquine—a drug commonly used for malaria—to a MEK inhibitor (tunlametinib) and an immunotherapy (pucotenlimab) can improve outcomes for people with advanced NRAS-mutant melanoma. The study aims to see if this combination can…

This study looks at whether giving radiation to the lymph nodes after surgery can lower the chance of melanoma returning in people who are already receiving immunotherapy. About 168 adults with high-risk melanoma that has spread to a sentinel lymph node will take part. The goal i…

This early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…

This study investigates whether aggressive lipid-lowering therapy can reduce plaque buildup in the heart arteries of melanoma patients starting immune checkpoint inhibitors (ICIs). Participants with plaque detected on a heart CT scan are randomly assigned to either usual care or …

This trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…

This study tests a new drug, T3011, in 42 people with advanced melanoma that has spread. The main goals are to check safety and see if tumors shrink. Participants must have measurable tumors and be in good overall health.

This trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…

This study tests a drug called ifinatamab deruxtecan (I-DXd) in people with 13 types of advanced solid tumors that have come back or spread. The trial aims to see how well the drug shrinks tumors and what side effects it causes. About 520 participants will receive the drug intrav…

This trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…

This Phase 2 trial tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to standard therapies. The treatment uses immune cells taken from the patient's own tumor, grown in a lab, and then given back to fight the cancer. About 98 particip…

This Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…

This early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…

This early-phase trial is testing whether adding sitagliptin, a diabetes drug, to the immunotherapy pembrolizumab is safe and can help people with advanced kidney cancer or melanoma whose cancer has stopped responding to standard treatment. The study will first find the safest do…

This early-phase trial is testing an experimental drug called INBRX-106, alone or combined with the immunotherapy Keytruda, in people with advanced solid tumors (including lung, head and neck, melanoma, and others) that have stopped responding to standard treatments. The main goa…

This phase II trial is testing an experimental drug called IBI363 in people with advanced melanoma that has worsened after at least one prior treatment. The study aims to see whether IBI363 is safe and can shrink tumors or slow their growth. About 180 participants will receive IB…

This study explores whether being physically active can help melanoma patients avoid or lessen the immune-related side effects of immunotherapy drugs like pembrolizumab and nivolumab. Researchers will track the activity levels of 160 adults starting immunotherapy and monitor them…

This early-stage study is testing an experimental drug called CTX-8371 in people with advanced lung, breast, lymphoma, head and neck, or skin cancers that have not responded to standard treatments. The main goal is to check the drug's safety and find the best dose. About 85 parti…

This Phase 1 trial tests whether HLX18, a biosimilar of the cancer drug OPDIVO, works similarly in people with esophageal, melanoma, or bladder cancer after their tumors have been surgically removed. About 174 participants will receive either HLX18 or OPDIVO to compare how the dr…

This trial investigates whether adding dried chicory root fiber to standard immunotherapy helps people with advanced melanoma. The fiber is meant to increase beneficial gut bacteria, which may in turn improve immune cell activity and the body's response to treatment. About 70 par…

This trial tests a new drug called N17350, a modified enzyme injected directly into tumors, in adults with advanced solid tumors that have not responded to standard treatments. The study aims to find the safest and most effective dose, and to see if the drug can shrink or stop tu…

This early-phase trial is testing a personalized vaccine made from each patient's unique tumor mutations. The vaccine is given along with an immune booster (poly ICLC) to help the body's T cells attack the cancer. The study includes up to 25 adults with advanced melanoma, breast …

This early-stage study tests a new drug called PF-08046054/SGN-PDL1V, alone or with another drug (pembrolizumab), in people with advanced solid tumors like lung, head and neck, esophageal, breast, stomach, endometrial, pancreatic, or liver cancer. The main goals are to find safe …

This phase 2 trial tests injecting two immunotherapy drugs (ipilimumab and nivolumab) directly into melanoma tumors before surgical removal. The goal is to shrink or eliminate the cancer while reducing the severe side effects that can occur when these drugs are given through a ve…

This early-phase trial tests a new combination treatment for people with advanced melanoma that has worsened despite standard immunotherapy. The treatment uses specially trained natural killer cells (either from the patient or a healthy donor) along with two immunotherapy drugs, …

This study tests a drug called tebentafusp combined with treatments directed at the liver (like embolization or chemo-embolization) for people with a rare eye cancer (uveal melanoma) that has spread to the liver. About 109 adults with a specific immune type (HLA-A*0201) will part…

This study tests whether adding the drug tarlatamab to standard radiation therapy is safe for people with cancers that have a protein called DLL3, including melanoma, lung cancer, and glioblastoma. About 30 adults with advanced or returning cancers will receive tarlatamab infusio…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or stopped responding to standard therapy. OBX-115 uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified in the…

This phase 2 trial is testing whether combining two immunotherapy drugs, nivolumab and relatlimab, can help control melanoma that has spread to the brain. About 30 adults with active brain metastases will receive the drugs by IV. Researchers will monitor side effects and how well…

This Phase 3 trial tests whether a genetically modified herpes virus (vusolimogene oderparepvec) combined with the immunotherapy drug nivolumab can help people with advanced melanoma that has stopped responding to prior treatments. About 400 participants will receive either the v…

This early-phase study tests a chemotherapy drug (gemcitabine) given as a mist to breathe in. It is for people whose solid tumors have spread to the lungs and who have no standard treatment options. The main goal is to find the safest dose and watch for side effects. Up to 44 par…

This early-stage trial is testing whether injecting a flu vaccine directly into melanoma tumors can help shrink them. The study includes adults with stage I to IV melanoma who have at least one tumor that can be injected. The main goals are to find the safest dose and to see what…

This early-stage study tests a new treatment called Adze1.C, a virus designed to infect and kill cancer cells while also boosting the immune system. It is for adults with advanced melanoma that has not responded to standard therapies. The main goals are to check the treatment's s…

This study tests whether giving a tetanus-diphtheria or polio vaccine during standard immunotherapy can help the immune system better attack melanoma tumors. About 25 adults with advanced melanoma will receive one of these vaccines after four cycles of checkpoint inhibitor therap…

This study tests pembrolizumab, a drug that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to other treatments. The main goal is to see if the drug can shrin…

This early-stage study tests a new drug called DXC014 in about 150 people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check safety, find the right dose, and see if the drug shows any signs of shrinking tumors.…

This study tests whether adding a personalized mRNA vaccine (V940) to standard immunotherapy (pembrolizumab) can stop advanced melanoma from growing or spreading. About 160 people with stage III or IV melanoma that cannot be removed by surgery will receive either the vaccine plus…

This study is for people whose melanoma has come back after standard treatment. Researchers want to see if giving two immunotherapy drugs (ipilimumab and nivolumab) before surgery can shrink the tumor and improve outcomes. About 25 adults will receive two cycles of these drugs, t…

This phase 1 trial tests a new drug called AWT020, given alone or with other cancer treatments, in people with advanced solid tumors such as non-small cell lung cancer, colorectal cancer, kidney cancer, and melanoma. The main goals are to check the drug's safety, find the best do…

This early-stage study tests a new oral drug, DEG6498, in about 100 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and understand side effects. Participants take the drug once daily and are closely monitore…

This study tests whether removing only the largest affected lymph node (instead of all nearby lymph nodes) after 6 weeks of standard immunotherapy works just as well for stage III melanoma. About 1500 adults with stage IIIB-D melanoma will be randomly assigned to one of the two s…

This Phase 3 trial is testing whether a powerful combination of two treatments works better than standard immunotherapy alone for people with advanced melanoma that has not been treated yet. The experimental approach uses lifileucel, a personalized therapy made from a patient's o…

This study tests a personalized treatment for advanced melanoma using a patient's own immune cells, called tumor-infiltrating lymphocytes (TIL), which are boosted with a protein called CD40L. After a short course of chemotherapy to make room, the enhanced cells are infused back a…

This study tests a new drug called XTX301 in people with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding a safe dose, and then testing that dose in specific cancer types. Researchers will monitor side effects and wheth…

This phase 2 trial is testing whether adding common diabetes drugs (metformin or rosiglitazone) to standard immunotherapy (nivolumab or pembrolizumab) can improve treatment for several advanced solid tumors, including melanoma, lung cancer, and liver cancer. About 72 participants…

This trial investigates whether combining two drugs, camrelizumab and famitinib, can help people with rare head and neck cancers that have spread or cannot be removed by surgery. The study includes four types of these cancers and aims to see how safe and effective the treatment i…

This early-stage trial tests an experimental drug called SAR445877, alone or with other cancer drugs, in adults with advanced solid tumors that have spread or cannot be removed. The study has two parts: first, finding a safe dose, and second, checking if the drug shrinks tumors. …

This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the dru…

This pilot study tests whether a surgical procedure called lymphovenous bypass (LVB) can prevent lymphedema (chronic swelling) when done at the same time as lymph node removal in melanoma patients. About 20 adults with melanoma who need axillary or inguinal lymph node dissection …

This early-phase study tests a new drug (IOV-3001) designed to boost immune cells in people with advanced melanoma that has not responded to prior treatments. About 42 adults will receive the drug alongside a personalized cell therapy called lifileucel. The main goals are to chec…

This early-stage trial is testing a new drug called AB821 in 50 adults with advanced melanoma or other solid tumors that respond to immune therapies. The main goal is to check safety and find the right dose. Participants receive AB821 by IV every 2 or 3 weeks for up to two years.

This early-phase trial is testing a new treatment called MEM-288, a virus designed to infect and kill cancer cells while also boosting the immune system. The study involves 40 adults with advanced solid tumors, including lung, skin, and breast cancers, who have not responded to s…

This Phase 2 trial tests whether adding thymosin alpha 1 to the immunotherapy drug toripalimab can help elderly patients (60+) with advanced melanoma. The study will enroll 55 participants and measure how many patients' tumors shrink or disappear. Researchers also want to see if …

This study tests a new drug, [212Pb]VMT01, that delivers a tiny dose of radiation directly to melanoma cells. It is being tested alone or with the immunotherapy nivolumab in 300 people with advanced melanoma that has worsened after prior treatment. The goal is to find safe doses …

This study tests a new treatment for people with stage IV melanoma that has spread to the brain. It combines a chemotherapy drug (temozolomide) with specially grown immune cells (NK cells) from a healthy donor. The goal is to see if this combination is safe and can shrink brain t…

This study tests a new treatment called IOV-4001 for people with advanced melanoma or non-small-cell lung cancer. The treatment uses a patient's own tumor-fighting immune cells, which are collected, genetically modified to remove a 'brake' called PD-1, and then infused back after…

This study looks at whether getting standard immunotherapy in the morning (before 11 am) or afternoon (after 12 pm) changes how well it fights advanced or metastatic solid tumors. Researchers think the body's internal clock (circadian rhythm) might affect immune activity. About 1…

This phase 2 trial tests the drug avapritinib in 50 adults with advanced solid tumors that have mutations in the CKIT or PDGFRA genes. The drug blocks enzymes that help cancer cells grow. The main goal is to see how many patients' tumors shrink or disappear. Researchers will also…

This study looks at whether taking a standard immunotherapy drug (PD-1 inhibitor) on an intermittent schedule works as well as taking it continuously for people with advanced melanoma that cannot be removed by surgery. About 614 participants will be randomly assigned to one of th…

This study tests a new drug called IDE196 in people with certain cancers that have specific genetic mutations (GNAQ/11 or PRKC fusions). The cancers include metastatic uveal melanoma, cutaneous melanoma, and colorectal cancer. The trial has two phases: first to find safe doses, t…

This early study tests whether giving an IL-17 blocker (secukinumab) alongside restarting immunotherapy can lower the risk of severe immune-related side effects in people with advanced melanoma. Only 4 participants who previously had side effects like colitis or rash will be enro…

This study is for people with high-risk melanoma who have tiny bits of tumor DNA still in their blood after surgery. It compares a two-drug immunotherapy combo against a single drug to see which better clears these hidden cancer cells. About 54 participants will be randomly assig…

This program provides the experimental drug ulixertinib to people with advanced solid tumors that have certain gene mutations (MAPK pathway). It is for patients who have not responded well to or have run out of standard treatments. The goal is to control the disease and possibly …

This study tests a new treatment made from donor immune cells (CAR-NK cells) that are designed to attack two targets on melanoma cells. It is for adults with advanced melanoma that has spread or cannot be removed and has not responded to standard therapies. The goal is to find a …

This early-stage trial tests a new drug called MST-0312, designed to help the body's immune system fight cancer more effectively. It is being studied alone or with another cancer drug (pembrolizumab) in people with several types of solid tumors, including lung, melanoma, bladder,…

This early-phase trial is testing a new drug called IACS-6274, either alone or combined with other cancer drugs, in 54 adults with advanced solid tumors (such as melanoma, ovarian, or head and neck cancers). The main goal is to find the safest dose and understand side effects. Th…

This study tests a new drug called ifinatamab deruxtecan in people with advanced solid tumors that have not been cured by other treatments. The goal is to find the safest dose and see if the drug can shrink tumors. About 250 participants will take part, and those who benefit may …

This Phase II trial tests two experimental drugs, JS212 and JS213, alone or together, in 410 adults with advanced solid tumors (kidney, prostate, bladder, or skin cancer). The main goal is to see if the drugs shrink tumors. Researchers will also check safety and how long any bene…

This early-phase trial tests whether adding an experimental drug called CBL0137 (Curaxin) to standard immunotherapy (ipilimumab and nivolumab) is safe for people with advanced melanoma that has spread. Only 12 participants will be enrolled, and the main goal is to check for side …

This study tests two new drug combinations (DB-1311 with BNT327 or DB-1305) in 450 adults with advanced or metastatic solid tumors that have not responded to other treatments. The main goals are to check safety and see if tumors shrink. Participants must be in fairly good health …

This study tests a type of internal radiation called high-dose-rate brachytherapy for people with liver tumors that cannot be surgically removed. The treatment uses a tiny radioactive source placed directly into the tumor to kill cancer cells while sparing nearby healthy tissue. …

This study tests a new treatment called KSQ-004EX for people with advanced solid tumors that have not responded to standard therapies. The treatment uses a patient's own immune cells (tumor infiltrating lymphocytes) that are genetically modified to be more powerful against cancer…

This early-stage trial tests a new immunotherapy for children and young adults up to age 21 with solid tumors that have come back or not responded to standard treatment. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack a protein…

This study tests a new drug called LBL-024, alone or combined with LBL-007 or toripalimab, in 200 people with advanced melanoma. The goal is to see if these treatments are safe and can shrink tumors. Participants receive the drugs through an IV, and doctors monitor side effects a…

This phase 2 trial is testing a combination of three immune-boosting drugs (relatlimab, nivolumab, and ipilimumab) in 60 people with melanoma that has spread to the brain. The study includes both patients with and without symptoms from their brain tumors. The main goal is to see …

This early-phase trial is testing whether a combination of two drugs—cadonilimab and a high-dose interferon—can safely shrink tumors in people with stage III or IV melanoma before they have surgery. Ten participants will receive the drugs for three months, and researchers will mo…

This phase 2 trial tests whether a combination of three drugs—fianlimab, cemiplimab, and ipilimumab—can safely shrink tumors in people with advanced melanoma that no longer responds to standard PD-1 therapy. The study enrolls 88 adults with locally advanced or metastatic melanoma…

This program offers early access to a combination of two immunotherapy drugs, botensilimab and balstilimab, for people with serious or life-threatening cancers like colorectal, pancreatic, lung, liver, melanoma, sarcoma, ovarian, or prostate cancer. It is for patients who have tr…

This early-phase trial is testing a new treatment called LauT-1 for people with advanced melanoma or sarcoma that has not responded to standard therapies. LauT-1 is made by taking a patient's own immune cells, modifying them in a lab to better recognize and attack their cancer, a…

This study tests a new treatment for people with solid tumors that have come back or not responded to standard care. The treatment uses a patient's own immune cells (T-cells) that are genetically modified in a lab to recognize and attack a protein called PRAME found on cancer cel…

This study is testing an experimental oral drug called RMC-6236 in adults with advanced solid tumors (like lung, colorectal, or pancreatic cancer) that have specific RAS mutations. The main goals are to find safe doses and understand side effects. About 754 participants will take…

This study is testing whether a low branched-chain amino acid (BCAA) diet, when combined with an immunotherapy drug (anti-PD-1), is safe and effective for people with stage III melanoma. About 80 participants will receive either the special diet or a normal diet alongside the imm…

This early-phase trial is testing a new virus-based cancer vaccine (PeptiCRAd-1) combined with the immunotherapy drug pembrolizumab in 15 people with various solid tumors like melanoma, triple-negative breast cancer, and lung cancer. The main goal is to see if the combination is …

This study tests whether adding an experimental drug (EIK1001) to standard immunotherapy (pembrolizumab) helps people with advanced melanoma live longer without their cancer growing. About 740 adults with stage 3 or 4 melanoma that cannot be removed by surgery will receive either…

This phase 3 trial tests darovasertib, a daily pill, given before standard local therapy (radiation or surgery) for people with uveal melanoma that hasn't spread. The goal is to see if the drug can prevent vision loss and avoid eye removal. About 520 participants will be randomly…

This study looks at whether adding a precise form of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain metastases in people with melanoma or non-small cell lung cancer. About 180 participants with newly diagnosed, untreated brain metastases w…

This study tests an experimental drug called REGN10597, alone or with another drug (cemiplimab), in people with advanced solid tumors like melanoma and kidney cancer. The goal is to see if the treatment is safe and can shrink tumors. About 240 participants will receive the drug i…

This study tests a new drug, LNS8801, taken as a daily pill, either alone or with the immunotherapy pembrolizumab, in people with advanced melanoma that has not responded to prior treatments. About 135 participants will be randomly assigned to one of three groups: LNS8801 alone, …

This program gives patients with advanced melanoma access to AMTAGVI, a cell therapy, even when the manufactured batch doesn't meet commercial standards but is still considered safe. It's for people who are already eligible for AMTAGVI and have a product made for them that failed…

This early-phase study tests an experimental oral drug called NST-628 in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 230 partic…

This early-phase study tests a new type of cell therapy for people with advanced melanoma that has not responded to standard treatments. The therapy uses a patient's own immune cells (NK cells) that are engineered in the lab to recognize and attack a protein called PRAME found on…

This study tests whether people with melanoma can safely avoid a second surgery (re-excision) after the initial tumor is removed with clear margins. About 1,749 adults with stage pT1b to pT4b melanoma will be randomly assigned to either standard follow-up care including re-excisi…

This phase II trial is testing two oral drugs, binimetinib and encorafenib, in 35 adults with advanced melanoma that has spread to the brain. The drugs block enzymes that help cancer cells grow. The study aims to see if this combination can control the disease and improve surviva…

This phase IIa trial is testing two experimental drugs, HX009 and IN10018, given together with or without standard chemotherapy, in 124 adults with advanced solid tumors, specifically biliary tract cancer and melanoma. The study aims to find the best dose and see if the combinati…

This early-phase study tests an injection of a modified herpes virus (RP1) directly into high-risk melanoma tumors. The goal is to see if it can kill cancer cells and reduce the chance of the cancer spreading to nearby lymph nodes. About 25 adults with thick or ulcerated melanoma…

This study tests an experimental oral drug called Alintegimod (7HP349) combined with two standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, and liver cancers. The trial has two parts: first, finding a safe dose (p…

This study tests a treatment called electrochemotherapy for people with tumors in organs like the liver or pancreas that cannot be removed by surgery. The treatment uses short electrical pulses to help chemotherapy drugs enter cancer cells more effectively. The goal is to shrink …

This study tests an experimental drug called TRK-950 in people with advanced solid tumors or melanoma that has not responded to standard treatments. The first parts check safety and side effects when given alone or with another cancer drug (nivolumab). The final part looks at whe…

This early-stage trial is testing a new treatment called VET3-TGI, a virus designed to infect and destroy cancer cells. It is being given alone or with the immunotherapy drug atezolizumab to 60 people with advanced solid tumors that have not responded to standard treatments. The …

This study tests whether a new drug called RP2, given with nivolumab, works better than the current standard combination (ipilimumab plus nivolumab) for people with metastatic uveal melanoma, a rare eye cancer that has spread. About 280 adults who have not had prior immunotherapy…

This phase 2 trial tests the immunotherapy drug nivolumab (Opdivo) given before and after surgery for people with stage III or IV melanoma. The goal is to see if tailoring treatment based on tumor biomarkers leads to better outcomes. About 90 participants will be enrolled at a si…

This early-phase trial tests a new treatment for people with advanced melanoma or other solid tumors that have spread. Doctors take a patient's own immune cells, modify them in a lab to better recognize and attack cancer, and give them back after a short course of chemotherapy. T…

This study is testing whether giving one dose of the immunotherapy drug pembrolizumab six weeks before surgery can help the immune system fight high-risk melanoma more effectively. About 49 adults with melanoma that hasn't spread on scans will receive the drug, then have their ly…

This study tests whether adding a low-dose chemotherapy drug (cyclophosphamide) to an immunotherapy (pembrolizumab) can shrink tumors in people with advanced melanoma that has stopped responding to standard immunotherapy. About 14 adults with stage III or IV melanoma that cannot …

This phase 2 trial is testing two oral drugs, belvarafenib and cobimetinib, in about 45 people with advanced or spreading melanoma that has a specific genetic change called an NRAS mutation. The goal is to see if the combination can shrink tumors and keep the disease under contro…

This study is for people with metastatic melanoma whose cancer has started growing in a few spots despite treatment. Researchers want to see if giving high-dose, precise radiation to those spots can delay further spread. About 52 adults will take part, and the main goal is to see…

This study tests an experimental drug called HMBD-501 in 180 adults with advanced solid tumors (melanoma, lung, or breast cancer) that have a protein called HER3 on their cells and have stopped responding to standard treatments. The trial has two phases: first, finding the safest…

This study tests a drug called tunlametinib in people with advanced melanoma that has a specific NRAS gene change and has not responded to prior immunotherapy. About 110 adults will take the drug by mouth to see if it can shrink tumors and how safe it is. The goal is to control t…

This study tests whether adding low-dose radiation to the liver before standard immunotherapy can help people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive radiation before their first three immunotherapy cycles. The …

This study tests whether adding an experimental drug (IMC-F106C) to standard immunotherapy (nivolumab) works better than standard treatment alone for people with advanced melanoma. About 680 adults with a specific genetic marker (HLA-A*02:01) and previously untreated advanced mel…

This study tests a new drug, tebentafusp, alone or with pembrolizumab, in people with a specific genetic type (HLA-A*02:01) of advanced melanoma that has been treated before. The main goal is to see if these treatments help people live longer compared to other available options. …

This study tests a new approach using immune cells from healthy donors, engineered to recognize and attack cancer cells. The target is chosen based on each participant's tumor profile. The trial includes 85 adults with advanced solid tumors that have not responded to standard tre…

This study tests whether giving new combinations of immunotherapy drugs before surgery can improve outcomes for people with advanced melanoma that is hard to treat. About 494 participants with stage 3 skin or mucosal melanoma will receive different drug combinations before their …

This study tests a new treatment called EBNK-001, made from donor immune cells (natural killer cells), in people with advanced solid tumors that have not responded to standard therapies. Participants receive the cells after chemotherapy to prepare the body, along with low-dose in…

This early-phase trial is testing a new drug called 177Lu-RAD204, which is a radioactive antibody designed to seek out and destroy cancer cells that have a protein called PD-L1 on their surface. The study will involve 30 adults with advanced solid tumors (like lung, breast, or sk…

This early-stage trial tests whether adding nilotinib to standard BRAF/MEK inhibitor therapy can help people with advanced melanoma whose cancer has stopped responding to treatment. About 30 participants will receive the drug combination to see if it is safe and tolerable. The go…

This study tests whether adding a prebiotic-rich diet to standard immunotherapy before surgery can improve immune response in people with melanoma. About 35 adults with resectable melanoma will receive prebiotic snack packs and diet counseling alongside their usual treatment. The…

This study is for people with stage IV melanoma that has spread to the brain. It compares two treatments: a combination of two immunotherapy drugs (ipilimumab and nivolumab) alone, or the same drugs plus precise, targeted radiation to the brain tumors. The goal is to see if addin…

This early-phase trial is testing a new drug called TGI-5, given alone or with the immunotherapy nivolumab, in people with advanced solid tumors such as colorectal, liver, lung, and skin cancers. The study aims to find safe doses and check for side effects in about 194 participan…

This study tests a new drug called TCC1727 combined with other medicines (benmelstobart, olaparib, or topotecan) in people with advanced solid tumors, including lung, stomach, endometrial cancer, and melanoma. The goal is to find the safest dose and see if the combination helps s…

This early-phase study tests JMT108, a bispecific antibody, in 270 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive JMT108 by …

This study tests whether MB11, a biosimilar (a nearly identical copy) of the cancer drug nivolumab (Opdivo), works as well as the original drug in people with advanced melanoma that cannot be removed by surgery or has spread. About 632 adults who have not yet been treated for the…

This study tests a new drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that haven't responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow cancer growth. A…

This early-phase trial tests a new treatment combining two experimental therapies (IMA203 and mRNA-4203) for people with advanced melanoma or synovial sarcoma that has not responded to prior treatments. The main goals are to check safety and find the best dose. About 15 participa…

This study tests whether adding the drug sarilumab to a standard immunotherapy combination can reduce severe side effects and work better for people with advanced melanoma that cannot be removed by surgery. About 105 participants will receive sarilumab along with ipilimumab, nivo…

This early study tests a new mRNA vaccine (IL-22BP) for people with advanced solid tumors like sarcoma, head and neck cancer, or melanoma that have not responded to standard treatments. The vaccine is injected directly into tumors. Only 6 participants are enrolled to check safety…

This early-stage trial tests a new drug called ONM-501, which is injected directly into tumors, either alone or with the immunotherapy cemiplimab (Libtayo). The study includes 168 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The m…

This Phase 3 trial tests whether injecting Daromun directly into melanoma tumors before surgery can help prevent the cancer from returning. About 186 people with stage IIIB/C/D melanoma will either get Daromun injections plus standard surgery and follow-up therapy, or just surger…

This study tests two different immunotherapy treatments given before surgery for stage III melanoma that can be removed. One group gets a single drug (PD-1 blocker), the other gets a two-drug combo (PD-1 and CTLA-4 blockers). The combo may work better but also has more side effec…

This early-phase trial tests a therapy made from a patient's own tumor-fighting immune cells (TILs) for advanced melanoma. Doctors take TILs from a tumor sample, grow them in the lab, and infuse them back after a short chemotherapy course. The study aims to see if this approach i…

This study tests two or three drugs (defactinib, avutometinib, and possibly encorafenib) in people with advanced melanoma that has spread to the brain. The goal is to see if these combinations can shrink brain tumors and how safe they are. About 33 adults whose melanoma worsened …

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participants with various cancers, including lung, mel…

This early-stage trial is testing a new drug called VSV-02 in 6 people with advanced solid tumors (like melanoma, breast, or lung cancer) who have no good treatment options left. VSV-02 is a modified virus that is injected into a vein and directly into the tumor, aiming to kill c…

This study follows 40 people who received Miltenyi CAR T cell therapy at least one year ago for cancers like melanoma, lymphoma, or leukemia. Researchers will track side effects, cancer return, and overall health for years. The goal is to understand the long-term safety and effec…

This trial is testing two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific genetic change called BRAF V600 mutation. The goal is to see if the combination can shrink tumors or stop them from growing. About 3…

This early-phase study tests a new drug called LB-LR1109 in people with advanced solid tumors like lung, kidney, head and neck, bladder, or skin cancer that has not responded to standard treatments. The study first gives the drug alone, then in combination with another cancer dru…

This trial tests the drug entrectinib (Rozlytrek) in people with rare cancers that have a specific genetic change called ROS1 fusion. The drug is already approved for some lung cancers, but researchers want to see if it works for other tumor types. About 30 adults, teens, and chi…

This trial tests atezolizumab, a drug already approved for several cancers, in people with rare cancers that have high tumor mutational burden (TMB) or microsatellite instability (MSI). The goal is to see if the drug can shrink tumors or stop them from growing for at least 24 wee…

This early-phase study tests a new drug called GV20-0251 in people with advanced solid tumors (like liver, lung, or skin cancer) that have stopped responding to standard therapies. The main goal is to check the drug's safety in a small group of 10 patients. It is not a cure, but …

This study tests an experimental drug called DB-1311/BNT324 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 862 adults will take pa…

This study tests an experimental treatment for adults with advanced melanoma who are already getting immunotherapy and planning surgery. The treatment combines focused ultrasound (using sound waves to heat and destroy tumor tissue) with an injection of a drug called polyICLC that…

This small pilot study is testing an oral drug called mirdametinib in 10 people with advanced melanoma that has a specific gene change (NF1 mutation) and has stopped responding to standard immunotherapy. The main goal is to see if the drug can shrink tumors and if it is safe enou…

This study tests whether giving standard immunotherapy drugs (ipilimumab and nivolumab) in the morning works better than giving them later in the day for people with advanced melanoma that has spread or cannot be removed. About 99 adults with stage IV melanoma will be randomly as…

This early-phase trial tests a new drug called STX-001, a self-replicating RNA that makes a protein to stimulate the immune system. It is injected directly into tumors, either alone or with the immunotherapy pembrolizumab (Keytruda). The study aims to find a safe dose and see if …

This early-stage trial tests a new treatment called T3011, a modified virus injected directly into tumors, for people with advanced solid cancers like melanoma, lung cancer, or sarcoma. The study will also test T3011 combined with the immunotherapy drug pembrolizumab (Keytruda). …

This study tests a vaccine made from modified melanoma cells in patients who had their tumors removed but are at high risk of recurrence. The vaccine is designed to train the immune system to recognize and attack any remaining cancer cells. Up to 50 participants will receive mult…

This phase 2 trial is testing a two-step treatment for people with BRAF-mutated melanoma that has spread to the brain and is causing symptoms. First, participants take two targeted pills (encorafenib and binimetinib) for about two months. Then, they receive two immunotherapy drug…

This early-phase study tests a personalized cell therapy for people with several types of advanced cancer that have spread and express a protein called NY-ESO-1. Participants receive a single infusion of their own immune cells that have been genetically modified to recognize and …

This early-phase trial tests a personalized vaccine made from a patient's own tumor cells or donor cells. The cells are modified and killed in the lab, then injected under the skin to train the immune system to attack the cancer. The study includes 50 adults with metastatic melan…

This study is testing whether removing only the cancerous lymph node in people with stage III melanoma can prevent the cancer from returning in that same area. Participants have one detectable cancerous lymph node and will undergo surgery to remove it, with or without additional …

This early-phase trial tests whether adding two stress-blocking drugs—naltrexone and propranolol—to standard immunotherapy (ipilimumab and nivolumab) is safe for people with advanced melanoma. The study aims to find the best dose and check for side effects in 12 participants. If …

This early-stage trial is testing an experimental drug called AMT-253 in about 96 people with advanced melanoma or other solid tumors that have not responded to standard treatments. The study has two parts: first, finding the safest dose, and then expanding to see how well the dr…

This early-phase trial tests a new cell therapy called Super1 TCR-T in 15 people with advanced solid tumors (sarcoma, lung cancer, or melanoma) that have not responded to first-line treatment. The therapy involves taking a patient's own immune cells, genetically modifying them to…

The ORACLE study watches people who have finished treatment for early-stage solid tumors, such as lung, breast, colon, and pancreatic cancers. Researchers want to see if a blood test called Guardant Reveal can find tiny traces of tumor DNA that might signal the cancer is coming b…

This trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…

This trial is investigating whether a new radioactive tracer called 18F-grazy-02, used with PET/CT scans, can safely and effectively monitor how well immunotherapy is working in people with lymphoma or solid tumors. The tracer targets granzyme B, a protein released by immune cell…

This study is testing a new device that uses light and sound to detect melanoma cancer cells flowing in the blood, without needing a blood draw. The goal is to see if it can find these cells faster and more sensitively than current lab tests. About 75 people with melanoma will be…

This study is testing a new radioactive imaging agent that targets a protein called LRRC15, found on many cancer cells. Researchers will use PET scans to see if this agent can better detect and stage cancers like pancreatic, breast, lung, and others. The trial includes 26 healthy…

This study is testing whether a telemedicine tool can help primary care doctors find skin cancer earlier. About 1,440 people with suspicious moles or lesions will have their skin checked remotely. The goal is to see if this approach can spot malignancies that might otherwise be m…

This study is testing a new platform that uses advanced testing to get a complete picture of a person's tumor. The goal is to see if this detailed information can help doctors choose better treatments for patients with high-risk cancers like leukemia, multiple myeloma, and pancre…

This study tests if a special ultrasound using a contrast agent (Sonazoid) can find sentinel lymph nodes as accurately as the standard radioactive tracer method in people with melanoma, breast cancer, or head & neck cancer. About 91 adults will take part, and the goal is to see i…

This early-phase trial is testing a new imaging agent (GEH200520/GEH200521) that lights up on PET scans to help see solid tumors. In Part A, 50 adults with advanced solid tumors will receive the agent and have scans to check safety and how the agent spreads in the body. Part B wi…

This phase 2 trial is testing whether a new radioactive tracer, [68Ga]Ga-FAPI-46, can improve how doctors evaluate response to immunotherapy in patients with stage IV melanoma. Twenty participants will receive two experimental PET/CT scans—one before starting immunotherapy and on…

This study is testing whether an AI-powered smartphone app (NuvanaDx) can accurately detect skin cancer, including melanoma, by analyzing photos of suspicious moles or lesions. About 100 adults with concerning skin spots will take part. The goal is to see if the app can help catc…

Researchers are testing whether sulforaphane, a substance found in broccoli and other cruciferous vegetables, can prevent melanoma in people who have multiple atypical moles and a prior history of melanoma. Participants take sulforaphane or a placebo by mouth. The trial measures …

This study tests a sun protection program for children playing baseball in rural Utah and West Virginia. Researchers will observe whether kids on teams using the program apply sunscreen, wear hats and long sleeves, and seek shade more often than those on teams that don't. The goa…

This study tests five different smartphone programs designed to help melanoma survivors reduce unprotected sun exposure. About 150 participants will wear a UV sensor and activity monitor, complete daily surveys, and use the programs for 8 weeks. The goal is to see which programs …

This study tests whether a procedure called lymphovenous bypass, done before underarm lymph node removal, can prevent lymphedema (arm swelling) in patients with breast cancer or melanoma. About 252 participants will receive the bypass during their cancer surgery. Researchers will…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps the immune system f…

This pilot trial tests a new approach to support cancer patients and their caregivers. The intervention combines social prescriptions—connecting people to community resources—with short online learning modules and regular symptom check-ins. The goal is to see if this package can …

This study tests whether an AI-based website that gives personalized diet tips and recipes can help cancer patients who experience taste changes during therapy. About 198 adults with certain cancers (like multiple myeloma, melanoma, or GI cancers) will either get the AI tool or a…

This study tests whether a digital tool combining weekly symptom surveys and a Fitbit can help monitor patients during immunotherapy for advanced melanoma. Forty participants will be randomly assigned to use the tool or receive usual care. The goal is to see if the system is easy…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if home treatment is preferred and improves satisfaction, while also checking safety. Participants will receive their usual cance…

This study is testing a program called MyCarePulse and ASCENT to help cancer patients overcome food-related challenges. About 100 adults recently diagnosed with certain cancers will either receive the program or standard care. The goal is to see if the program improves food secur…

This study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …

This study tests whether a diet rich in prebiotic foods can improve the gut microbiome and enhance the effectiveness of first-line immunotherapy in people with advanced melanoma that cannot be removed by surgery. Researchers will enroll 75 adults starting standard immunotherapy a…

This study looks at whether a 12-week supervised exercise program can reduce fatigue and improve quality of life in adults with stage IIb-IV melanoma who are receiving immunotherapy or targeted therapy. Participants are randomly assigned to either an exercise group (online sessio…

This study compares two surgical techniques—perforator flap versus skin graft—for repairing the wound left after removing a stage II melanoma. Researchers want to see which method leads to faster wound healing and better quality of life. Forty adults with melanoma on the trunk, a…

This study follows 350 people with stage III-IV melanoma during their first two years after diagnosis to understand how their quality of life and mental health change. It also tests whether cognitive behavioral therapy for cancer distress (CBT-C) can help reduce stress, improve s…

This study compares giving the cancer drug nivolumab (Opdivo) as a shot at home versus in a clinic for people with various advanced cancers. The goal is to see if home treatment improves patients' overall care experience and quality of life. About 50 adults will receive the drug …

This study tests whether a short bout of cycling exercise right before immunotherapy (nivolumab and ipilimumab) can boost the immune system and improve treatment outcomes in people with advanced melanoma. Researchers want to see if this approach is practical and safe for patients…

This study compares two approaches to supportive cancer care for nearly 3,000 adults with cancer. One group gets information through email or their health record, while the other works one-on-one with a lay health worker over 12 months. The goal is to see which model better impro…

This study tests whether adding cryoablation (a procedure that freezes and kills cancer cells) to standard radiation therapy provides better pain relief for people whose cancer has spread to their bones. About 40 participants with various cancers will be split into two groups: on…

This study looks at whether people with certain cancers prefer getting their immune therapy as a shot under the skin (subcutaneous) or through a needle in a vein (intravenous). About 880 adults who are already eligible for standard treatments like nivolumab or pembrolizumab will …

This study tests whether EMLA numbing cream can reduce pain from Technetium 99 injections used in lymphoscintigraphy, a standard mapping procedure for skin cancers like melanoma. About 100 adults with skin cancer will receive either EMLA cream or a placebo before the injection. T…

This study tests whether a single dose of NPX-5 (a psilocybin drug) combined with talk therapy can reduce severe anxiety in people who have trouble adjusting to a cancer diagnosis. About 87 adults aged 18–80 with moderate-to-severe anxiety will receive one of three doses (25 mg, …

This study tests whether urolithin A, a dietary supplement, can improve the immune system's response to standard immunotherapy drugs in people with newly diagnosed solid tumors like lung cancer or melanoma. 45 participants will be randomly assigned to receive either urolithin A o…

This study tests whether fecal microbiota transplantation (FMT) capsules can help people with diarrhea and colitis caused by immune checkpoint inhibitor cancer treatment. About 20 adults with melanoma or kidney cancer will receive either FMT or placebo capsules alongside their st…

This study aims to understand how genetics and environmental factors contribute to melanoma, a serious skin cancer. Researchers will enroll up to 3,000 people with a personal or family history of melanoma or related conditions. Participants will fill out questionnaires, provide b…

This observational study in Vietnam looks at archived tumor samples from patients with several solid cancers, including liver, colorectal, gastric, breast, lung, endometrial, melanoma, and pancreatic cancer. Researchers will measure the presence of two proteins, ENPP1/cGAS and FA…

This study screens adults with certain cancers (like melanoma, lung, or colorectal cancer) to see if they qualify for experimental treatments being tested by the NCI Surgery Branch. These treatments involve taking a patient's own immune cells, growing them in a lab, and giving th…

This study looks at whether using genetic markers from a child's skin tumor can help doctors decide how much surgery is needed. About 51 children and young adults up to age 25 with localized melanoma or similar growths will have their tumor tissue reviewed centrally. Based on ris…

This study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…

This study is a large registry that collects health information and leftover tumor or blood samples from up to 75,000 children and young adults with cancer. The goal is to track outcomes and gather data to help doctors find better ways to treat and care for these patients over ti…

This study tests tumor tissue from up to 12,000 cancer patients to find gene changes (mutations). The goal is to match each patient with a clinical trial or therapy that targets their specific cancer type. Researchers will also build a database of mutations to help future patient…

This study enrolls 7,000 people with various cancers who have had or will have treatment aimed at a cure. Researchers collect blood, tissue, urine, and saliva samples over time to look for tiny bits of cancer DNA left behind. The goal is to find any remaining cancer as early as p…

This study will follow 600 people with early-stage solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy before surgery. Researchers will collect blood and tumor samples at several time points to see how the immune system responds. …

This study is testing whether a mobile app called Vigilant can help monitor side effects in 100 people with skin cancer or melanoma who are starting a specific type of immunotherapy. Participants will use the app to report any symptoms they experience, and researchers will track …

This early-stage study tests whether people with advanced solid tumors can safely follow a diet low in methionine, an amino acid found in many proteins. Researchers will measure how well participants stick to the diet, check for side effects, and track changes in blood methionine…

This study looks at whether adding a high-fiber diet and short-term fasting can help melanoma patients undergoing immunotherapy. Forty participants will follow a high-fiber diet, with half also doing 72-hour fasts during each treatment cycle, while 20 others serve as a control gr…

This study tests whether a digital tool called MySmartSkin can help melanoma survivors do better skin self-exams. About 385 survivors will use either the enhanced app or a standard educational webpage. The goal is to see if the app leads to more thorough skin checks and earlier d…

This study looks at how the bacteria in your gut might cause stomach issues like diarrhea and colitis when you take certain cancer drugs called immune checkpoint inhibitors. Researchers will collect stool, blood, and tissue samples from 800 people with melanoma, lung cancer, or g…

This study is for young adults (ages 21-45) who had certain cancers as teens or young adults. Researchers are adapting a program that helps survivors manage their health after cancer treatment. The goal is to see if this program improves survivors' confidence and ability to handl…

This study observes patients with high-risk stage II melanoma to see if starting anti-PD-1 immunotherapy before surgery leads to better outcomes compared to the usual timing after surgery. Researchers will track when patients begin systemic therapy and compare results between the…

This study is building a huge registry of information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. Researchers will use this resource to study what causes cancer and how to better prevent, detect, and treat it. The re…

This study is collecting live tumor samples from 2,000 cancer patients undergoing standard biopsies. Researchers will analyze these samples to understand how tumors respond to immunotherapy drugs outside the body. The goal is to develop a method to predict which patients will res…

This study aims to discover new genes that may cause certain cancers to run in families. Researchers will collect blood samples and health information from 1,500 people in families where multiple members have had cancer, especially childhood cancers. The goal is to build a regist…

This study from Mayo Clinic is looking at how T cells (a type of immune cell) change during anti-PD-1 immunotherapy in people with advanced melanoma, lung cancer, or other solid tumors. Researchers will collect blood and tissue samples from 500 participants to measure specific ma…

This study tracks 770 adults with advanced solid cancers (like lung, head and neck, melanoma, or bladder cancer) who are receiving immunotherapy. Researchers collect tumor and blood samples over time to find biological markers that predict how well the treatment works or causes s…

This study is looking for certain cells in the blood of people with 9 types of advanced cancers that have spread. Researchers will take one blood sample from each of 450 participants before they start a new treatment. They will use two different lab methods to see if they can fin…

This study is collecting detailed genetic and health information from 500 people with various cancers, including breast, lung, and leukemia. The goal is to create a shared database that helps researchers develop more personalized treatments. Participants provide samples and data,…

This study looks at melanoma tumors that spread between the main tumor and nearby lymph nodes (called in-transit metastases). Researchers will take biopsies from different spots and use a safe tracer to measure oxygen levels. They aim to understand how these tumors change metabol…

This study is investigating whether low oxygen levels (hypoxia) in melanoma tumors and nearby lymph nodes are linked to worse outcomes. Researchers will give 50 patients a safe oral tracer called pimonidazole before their standard surgery. By measuring hypoxia in the removed tiss…

This pilot study explores whether eating high-fermented foods (like yogurt and kimchi) followed by high-fiber supplements can change the gut microbiome and improve immune response in people with melanoma or lung cancer who are receiving standard immunotherapy. Researchers will tr…

This study is creating a large collection of blood and tissue samples from people with skin cancer and healthy volunteers. Researchers will store these samples and medical data to support future studies on skin cancer. The goal is to provide a valuable resource for translational …

This study looks at whether the bacteria naturally found in urine can help doctors better understand melanoma, a serious skin cancer, and predict how well patients will respond to treatment. Researchers will collect urine and stool samples from 50 people with advanced melanoma st…

This study aims to collect and analyze tumor samples from 10,000 adults with advanced solid cancers (like breast, lung, or colon cancer) to create a province-wide gene database. The goal is to help doctors identify which targeted drugs or clinical trials might work best for each …

This study looks at how melanoma tumors process energy, specifically glucose, to see if certain metabolic patterns are linked to cancer spread. Researchers will give a special glucose tracer to 400 adults with melanoma before their surgery and analyze the tumor tissue. Participan…

This study is testing whether an 8-minute educational video can effectively prepare cancer patients for genetic testing, compared to standard genetic counseling. Over 1,000 adults with various cancers will participate. The goal is to see if the video is acceptable and improves un…

This study is testing an educational tool designed for people with melanoma who also have an autoimmune disease and are considering treatment with immune checkpoint inhibitors. Researchers want to see if the tool is easy to use and helpful for both patients and healthcare provide…

This study enrolls 200 people with acral or cutaneous melanoma who are starting standard immunotherapy. Researchers will collect blood samples every 3 weeks and tumor tissue after about 3 months of treatment. By analyzing circulating tumor cells, DNA, and other markers, they aim …

This study is for people with advanced cancers who are taking long-term targeted treatments. Researchers want to learn about their experiences through interviews. The goal is to find better ways to support these patients. The study is currently recruiting 75 participants.

This study looks at how immunotherapy drugs (anti-PD-1) affect bone strength in people being treated for cancer. Researchers will measure bone density and blood markers over a year in 25 patients. The goal is to understand if these treatments increase fracture risk, so doctors ca…

This study looks at how lifestyle factors like diet, exercise, mental health, and social support affect quality of life and outcomes in people with melanoma. Researchers will follow 5,000 participants over time using surveys and medical records. The goal is to gather knowledge th…

This study collects blood, urine, and bone marrow samples from 620 people with solid cancers like lung, colorectal, and pancreatic cancer. Researchers will look for tumor cells and DNA in these samples to understand how cancer spreads and why it sometimes comes back after surgery…

This study uses online surveys to learn about the real-life experiences of people diagnosed with cancer and their caregivers. Researchers want to understand the emotional, physical, social, and financial challenges they face. The goal is to use this information to improve support…

This study uses a 10-minute questionnaire to learn how the COVID-19 pandemic impacted the quality of life, mental health, finances, and social connections of people with melanoma. Researchers will also look at what factors, like social support, helped people cope. About 1,152 par…

This study aims to develop an artificial intelligence (AI) algorithm that analyzes skin damage (dermatoheliosis) around a melanoma scar to predict whether a patient will respond to anti-PD-1 immunotherapy. Researchers will collect photos and medical data from 700 adults with adva…

This study follows 2,000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps with symptoms like pain or nausea over time. No treatme…

This study is looking for better ways to predict who might develop or have a return of certain cancers, including breast, colon, ovarian, melanoma, and lung cancer. Researchers will collect blood samples from 850 participants to study genetic and other biological markers. The goa…

This study is looking for 500 people with certain cancers (like eye or skin melanoma, kidney cancer, or mesothelioma) and their family members to understand how common BAP1 gene mutations are. Researchers will collect medical history and questionnaires to learn about cancer risks…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find cancer returning earlier than standard scans. About 100 people with different solid tumors will give blood samples after treatment. The goal is to see if early detection can lead to better treatm…

This study is tracking 100 people in Slovenia with advanced melanoma who are receiving first-line immunotherapy drugs like pembrolizumab, nivolumab, or ipilimumab. Researchers want to see how well these treatments work and whether a marker called PD-L1 in tumors or blood can pred…

This study is tracking 40 people in Slovenia with metastatic melanoma who are receiving standard first-line immunotherapy. Researchers want to see how well the treatment works and look for clues in blood, stool, and tumor samples that might predict who will benefit most. The goal…

This study collects blood and tumor samples from 1,000 people with melanoma and healthy volunteers. Researchers will analyze these samples to learn more about what causes melanoma and how tumors behave. The goal is to find new markers that could lead to better diagnosis or treatm…

This study looks at how electrochemotherapy—a treatment that uses electric pulses to help chemotherapy drugs enter cancer cells—changes the environment around melanoma skin tumors. Researchers will collect tissue samples from 150 adults before and after treatment to see how immun…

This study looks at how immune checkpoint inhibitors (ICIs), a common treatment for melanoma, may affect the reproductive organs and sex hormones in men and women. Researchers will collect blood samples and questionnaires from 80 participants during their regular treatment visits…

This study looks at how a standard immunotherapy drug (anti-PD1) changes the appearance and biology of atypical moles in people with advanced melanoma. Researchers will track 30 patients to see if the drug alters mole size, color, and cellular features. The goal is to better unde…

This study looks at 24 people with advanced melanoma who are starting immunotherapy. Researchers will do a special PET/CT scan and a blood test for tumor DNA about 3-4 weeks after the first treatment. The goal is to see if these early tests can predict whether the immunotherapy i…

This study collects blood and leftover tissue samples from 9,600 people with various cancers, including breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for cancer DNA in the blood. The goal is to better detect if cancer returns o…

This study watches 50 people who already received a replimune oncolytic immunotherapy for cancers like melanoma or liver cancer. The goal is to check for any delayed side effects over 5 years. No new treatment is given—just regular check-ins to see how patients are doing.

This study is for people with solid tumors that have spread to the brain. Researchers want to collect medical information and samples (like blood and spinal fluid) to better understand why and how brain metastases happen. The goal is to find new ways to treat or prevent them in t…

This study is investigating why some melanomas stop responding to immunotherapy. Researchers will take biopsies from 20 patients with advanced melanoma before and after treatment to see how tumor metabolism changes. The goal is to understand resistance mechanisms and find new way…

This study reviews medical records of 221 people with advanced melanoma who received immunotherapy between 2013 and 2021. The goal is to find new factors that predict which patients achieve a complete and lasting response. Participants must be 18 or older and have received treatm…

This observational study is looking at 25 adults aged 18 to 39 who have been diagnosed with melanoma. Researchers want to find out how common melanoma is in this age group and identify risk factors, skin features, and genetic changes linked to the disease. The goal is to better u…

This observational study in Italy will examine the link between work-related sun exposure and melanoma. Researchers will interview 300 people (120 with melanoma, 180 without) about their job history, sun habits, and protection use. The goal is to better understand how outdoor wor…

This study looks at 200 people with suspicious moles that are already scheduled for removal. Researchers will use a special microscope (reflectance confocal microscopy) to take detailed images of the moles and then compare those images with genetic tests from the removed tissue. …

This study aims to create a large collection of blood samples from 2,500 people with or at high risk for cancer. Researchers will use these samples to study liquid biopsies, which are blood tests that may help detect cancer, track treatment response, and spot recurrence. Particip…

This study tracks 100 cancer survivors aged 18–74 to see how common muscle loss (sarcopenia) and cognitive problems ('chemo brain') are after treatment. Participants undergo physical and mental assessments. The goal is to better understand these long-term side effects and guide p…

This study tracks fertility markers in 80 melanoma patients (women aged 18-37, men aged 18-45) before, during, and after adjuvant therapy with anti-PD-1 or targeted treatments. Researchers measure hormone levels in women and sperm quality in men to see how these change over time.…

This study collects tumor samples from 500 children and teens with melanoma or related skin growths to analyze their genetic makeup. Researchers aim to learn more about what drives these rare childhood cancers. No new treatments are being tested; instead, the focus is on gatherin…

This study follows 300 adults with advanced melanoma who are receiving immune checkpoint inhibitors. Researchers will collect blood samples, quality-of-life surveys, and medical records to track symptoms over time. The goal is to identify patterns and risk factors for worse sympt…

This study looks at whether beta-glucan, a natural fiber from yeast, can improve the immune response to the immunotherapy drug pembrolizumab in people with stage III or IV melanoma. Researchers will measure changes in immune cells from blood samples. The goal is to understand how…

This study is testing whether an artificial intelligence (AI) tool can help match cancer patients with the right clinical trials. Researchers will enroll up to 50,000 people with various cancers to see if the AI improves trial enrollment rates and patient outcomes. The goal is to…

This study collects samples from 320 people, including those with solid cancers (like lung, colon, or pancreatic cancer) and those undergoing lung cancer screening, to look for cancer cells and DNA in blood, urine, and bone marrow. The goal is to learn how cancer spreads and find…

This study tests whether eating dried chicory root (a high-fiber prebiotic) every day for 6 weeks can change gut bacteria and immune cells in 20 people who had surgery for stage II melanoma. Researchers want to see if it increases helpful substances called short-chain fatty acids…

This study collects and stores tissue and blood samples from up to 3,000 melanoma patients to understand the biological changes that drive the disease. Researchers will analyze the samples to identify molecular markers that may help doctors choose the most effective treatments. T…

This study is testing a new predictive model that analyzes tumor samples to forecast whether a patient with melanoma or other skin cancers will respond to immunotherapy. Researchers will compare the model's predictions with actual patient outcomes over six months. The goal is to …

This study looks at whether a quick ultrasound of the thigh muscle can detect muscle loss (sarcopenia) in people who have finished cancer treatment. Researchers will compare the ultrasound results with a standard whole-body scan (DEXA) in 55 adults aged 18-74 with certain cancers…

This study uses a special eye scan called OCT angiography to look at iris tumors in 100 people. Researchers want to see if this scan can tell the difference between harmless and cancerous growths better than current methods. Participants include people with iris tumors and health…

This study follows 270 women under 40 who have had melanoma removed and are now taking adjuvant therapies like dabrafenib, trametinib, pembrolizumab, or nivolumab. Researchers will measure ovarian reserve using a blood test before and after treatment to see how these drugs affect…